moxaverine
Small moleculeexperimental
Moxaverine has been used in therapy based on the direct vasodilatory effect of the drug, a phosphodiesterase inhibitor, and on its influence on the rheological properties of red blood cells. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2007 (NCT00569621)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
CCc1cc2cc(OC)c(OC)cc2c(Cc2ccccc2)n1- Mol. weight
- 307.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMoxaverine ↗
- ChEMBLCHEMBL2105060 ↗
Also known as
- 1-benzyl-3-ethyl-6,7-dimethoxyisoquinoline
- certonal
- eupaverin
- eupaverin
- kollateral
- moxaverin
- moxaverine
- moxaverine
- moxaverine
- moxaverine
- moxaverine
- moxaverine
- moxaverine
- moxaverine hydrochloride
- moxaverine sulfate (1:1)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01629680 | Phase 2 | Oct 1, 2010 | University of Vienna |
| NCT00709449 | Phase 2/Phase 3 (Phase 3) | May 1, 2008 | University of Vienna |
| NCT00569621 | Phase 2 | Mar 1, 2007 | University of Vienna |
| NCT00709423 | Phase 2 | Mar 1, 2007 | University of Vienna |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Vienna | Academic/Hospital | 4 | 4 | 2 | 2007 |
1 organizations
Page 1 / 1